- $121.93bn
- $140.83bn
- £32.67bn
- 98
- 63
- 99
- 99
REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - ViiV’s cabotegravir superior for HIV prevention
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK sets new environmental goals
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Holding(s) in Company
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - 3rd Quarter Results
AnnouncementREG - GlaxoSmithKline PLC - Sanofi and GSK support COVAX - 200m vaccine doses
AnnouncementREG - GlaxoSmithKline PLC - Holding(s) in Company
AnnouncementREG - GlaxoSmithKline PLC - Positive CHMP opinion ViiV long-acting HIV regimen
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement